Fig. 4

Pulmonary delivery of INC280-PFCE NPs inhibits orthotopic NSCLC progression. A Schematic diagram showing the treatment regimen for the model animals with orthotopic NSCLC. The mice were divided into 4 groups, Control, PFCE NPs, INC280 and INC280-PFCE NPs (n = 13 per group). PFCE NPs group: a single 50 µL of PFCE NPs was administered by IT instillation. INC280 group: free INC280 was orally given at 3 mg/kg every day and total drug doses were 840 µg in a 14-day treatment cycle. INC280-PFCE NPs group: a single dose 50 µL of INC280-PFCE NPs (with an INC280 content of 89.8 µg in total per treatment cycle of 14 days) groups were administered by IT instillation. B After different treatments, representative T1-weighted MR images of the mice at different time points. C Individual tumor growth curves of mice treated with PBS, PFCE NPs, INC280 or INC280-PFCE NPs (n = 5). D After 14 days of treatment, the weights of the tumors of the orthotopic NSCLC model mice (n = 5). E Survival curves of the tumor-bearing mice after receiving different treatments (n = 8). F On day 14 posttreatment, representative photos of lung tumors excised from the orthotopic NSCLC model mice after different treatments. The scale bar is 1 cm. G Body weights of the orthotopic NSCLC model mice after different treatments as a function of time (n = 5). H Histopathological analysis of the tumors harvested from the orthotopic NSCLC model mice after different treatments. Scale bar is 100 µm. The results are presented as mean ± standard deviation. * P < 0.05, ** P < 0.01, *** P < 0.001 and **** P < 0.0001